Jae Yong Cho
Overview
Explore the profile of Jae Yong Cho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
4971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han J, Koh M, Boussi L, Sorial M, McCabe S, McCabe S, et al.
Blood Adv
. 2024 Oct;
9(3):583-602.
PMID: 39481087
Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural...
2.
Kim B, Maeng C, Keam B, Im Y, Ro J, Jung K, et al.
Cancer Res Treat
. 2024 Jul;
57(1):39-46.
PMID: 38993093
Purpose: The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to...
3.
Kim Y, Choi Y, Joo D, Baek W, Suh Y, Oh W, et al.
Yonsei Med J
. 2024 Jan;
65(2):108-119.
PMID: 38288651
Purpose: With the revision of the Organ and Transplantation Act in 2018, the hand has become legal as an area of transplantable organs in Korea. In January 2021, the first...
4.
Jo J, Kim Y, Choi H, Kim H, Lee H, Choi Y, et al.
Br J Cancer
. 2023 Dec;
130(1):163.
PMID: 38049557
No abstract available.
5.
Jo J, Kim Y, Choi H, Kim H, Lee H, Choi Y, et al.
Br J Cancer
. 2023 Oct;
130(1):43-52.
PMID: 37903909
Background: The TeloVac study indicated GV1001 did not improve the survival of advanced pancreatic ductal adenocarcinoma (PDAC). However, the cytokine examinations suggested that high serum eotaxin levels may predict responses...
6.
Kim B, Kim Y, Cho J, Lee K
Ann Lab Med
. 2023 Oct;
44(2):164-173.
PMID: 37903652
Background: Molecular cancer profiling may lead to appropriate trials for molecularly targeted therapies. Cell-free DNA (cfDNA) is a promising diagnostic and/or prognostic biomarker in gastric cancer (GC). We characterized somatic...
7.
Vaid R, Mendez A, Thombare K, Burgos-Panadero R, Robinot R, Fonseca B, et al.
Genome Res
. 2023 Mar;
33(3):299-313.
PMID: 36859333
Insights into host-virus interactions during SARS-CoV-2 infection are needed to understand COVID-19 pathogenesis and may help to guide the design of novel antiviral therapeutics. -Methyladenosine modification (mA), one of the...
8.
Khan I, Baig M, Mahfooz S, Imran M, Khan M, Dong J, et al.
Semin Cancer Biol
. 2022 Jun;
86(Pt 2):172-186.
PMID: 35760272
Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality and morbidity rates. Current treatment for patients with glioblastoma includes maximal safe tumor resection followed by...
9.
Kim B, Kim Y, Shin S, Lee S, Cho J, Lee K
Cancer Cell Int
. 2022 Feb;
22(1):82.
PMID: 35168603
Background: Approximately 50%-60% of secondary resistance to primary EGFR- tyrosine kinase inhibitors (TKI) therapy is caused by acquired p.Thr790Met (T790M) mutation; however, highly fragmented, low-quantity circulating tumor DNA is an...
10.
Khan M, Baig M, Mondal T, Alorabi M, Sharma T, Dong J, et al.
Viruses
. 2021 Nov;
13(11).
PMID: 34835101
The recent emergence of novel SARS-CoV-2 variants has threatened the efforts to contain the COVID-19 pandemic. The emergence of these "variants of concern" has increased immune escape and has supplanted...